middle.news
Percheron Therapeutics Launches Vanderbilt-Led Trial for HMBD-002 in AML
8:11am on Friday 28th of August, 2026 AEST
•
Biotechnology
Read Story
Percheron Therapeutics Launches Vanderbilt-Led Trial for HMBD-002 in AML
8:11am on Friday 28th of August, 2026 AEST
Key Points
Vanderbilt Health to lead multi-centre HMBD-002 trial in AML/MDS
Trial combines HMBD-002 with azacitidine and venetoclax
Investigator-sponsored trial design with FDA interactions led by Vanderbilt
HMBD-002 targets immune checkpoint VISTA, implicated in therapy resistance
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Percheron Therapeutics (ASX:PER)
OPEN ARTICLE